Study on blood apolipoprotein as a potential biomarker of neurodegenerative diseases
10.16438/j.0513-4870.2021-0746
- VernacularTitle:血液载脂蛋白作为神经退行性疾病潜在生物标志物的研究
- Author:
Fang ZHANG
;
Xiao-liang WANG
- Publication Type:Research Article
- Keywords:
neurodegenerative disease;
Alzheimer's disease;
Parkinson's disease;
multiple sclerosis;
amyotrophic lateral sclerosis;
ataxia;
blood biomarker;
apolipoprotein
- From:
Acta Pharmaceutica Sinica
2021;56(6):1513-1520
- CountryChina
- Language:Chinese
-
Abstract:
Neurodegenerative diseases (ND) mainly include Alzheimer's disease, Parkinson's disease, multiple sclerosis, amyotrophic lateral sclerosis, ataxia, and other diseases. The number of patients with ND is increasing, but the proportion of patients who can be diagnosed and treated early is less than 30% and the cause of ND is still unclear. In order to intervene in the disease as early as possible, researchers are committed to finding biomarkers that facilitate the early diagnosis of ND. Among them, cerebrospinal fluid (CSF) closely reflects the composition of the extracellular space of the brain, and may be the most sensitive biomarker for evaluating ND. However, the method of taking cerebrospinal fluid is more complicated, and it is not a common method in primary care or elderly medical institutions for the treatment of ND patients. Imaging examinations are expensive and difficult to spread among the community. The peripheral blood collection is convenient and less traumatic, which is a potential early screening and follow-up method. There are many components in the blood for analysis and research. This article reviews the research progress of the changes of apolipoprotein in the blood of ND patients as markers.
